GWPH News and Press, GW Pharmaceuticals Plc From 11/12/20

Zogenix just launched Fintepla, a product to treat Dravet syndrome. GW Pharma already has a Fintepla competitor Epidiolex approved and growing big sales in Dravet syndrome and other indications that Fintepla will likely expand to. Zogenix’s major sell-off makes its valuatio...

Company saw a surprise upside in revenues and earnings for the latest quarter. Strong pipeline means a continued revenue stream into the future. More acceptance of cannabis products by medical professionals, governments, and patients means more opportunity for continued growth. ...

During a recessionary environment is historically when VCs make a ton of money. Narbe Alexandrian, President and CEO of Canopy Rivers, the venture capital arm of Canopy Growth, returns to the show. We discuss its portfolio, TerrAscend capitalizing on New Jersey going legal, and bu...

Cannabis stocks are getting a lot of attention, but what about cannabis exchange-traded funds (ETFs)? Now that the cannabis industry is beginning to mature, these marijuana-focused investment vehicles have become a budding part of the overall financial market. Understandably...

LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the S...

Innovative Industrial Properties (IIPR) reported its latest financial results this week and they were spectacular. Learn what this means for the company and if you should consider buying the stock. Cannabis investors got great news earlier in the week, as GW Pharmaceuticals ( GWPH ) ...

Despite not officially deciding the presidential election, american’s made it clear they wanted legal cannabis as five states passed some form of legalization. Arizona, Montana, New Jersey, and South Dakota have all legalized marijuana for adults 21 and older, as voters i...

GW Pharmaceuticals' latest earnings report reinforces the narrative that the company's future growth trajectory looks solid. Epidiolex still has a lot of growth potential in the short and long term, with a lot of market share remaining to be taken in different segments. For now th...

Cannabis investors got come good news this week as GW Pharmaceuticals (GWPH) reported better than expected results. Learn what drove these results and what they mean for the company going forward. It’s no secret that the cannabis industry has struggled, with the ETFMG Alternative ...

Why These Marijuana Stocks Are Still On Top As November starts off strong, many investors are still working to find marijuana stocks to watch . Of course, we have obvious choices like Green Thumb Industries Inc. ( GTBIF Stock Report ) and GW Pharmaceuticals Inc. ( GWPH Stock R...